Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on Reckitt Group

(Sharecast News) - Analysts at Berenberg raised their target price on consumer goods giant Reckitt Group from 5,177.0p to 5,920.0p on Friday but warned of "risks on all sides" as 2025 unfolds. Berenberg noted that Reckitt's recently released FY24 showed Q424 group like-for-like sales growth of 4.6%, below visible alpha consensus expectations of 5.5%, driven by price/mix of 2.8% and volumes of 1.8%.

At the divisional level, Berenberg pointed out that hygiene achieved like-for-like sales growth of 5.5%, health was up 2.4%, and nutrition sales were 8.4% higher. Actual group sales of £3.54bn came in roughly 1% below consensus expectations but FY24 adjusted operating margins of 24.5% at the group level were well ahead of consensus forecasts of 23.3%, driving a 5% beat on adjusted operating profits.

For 2025, Berenberg forecasts like-for-like sales growth of 2.8%, down from 5.0%, an FX impact on sales of -2.1%, an adjusted EBIT margin of 25.0%, and net finance costs of £351.0m.

"Our 2025 EPS estimate is unchanged at GBP3.49. Our 12-month price target rises to 5,920p (previously 5,177p), driven by the roll-forward of our DCF model and reflection of lower bond yields (0.2% lower WACC)," said the German bank, which maintained its 'hold' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.